Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 master protocol of volrustomig combinations in colorectal cancer
NL-OMON59979Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of volrustomig in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Safety and tolerability. Started Jul 2025; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59979.